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ABSTRACT 
Plasma Y-melanotropin was measured by a Y3MSH-specific radioimmunoassay 
before and after a single bolus intravenous infusion of ovine corticotropin 
releasing factor (0CRF; 0.1 ug/kg) in seven normal men. A significant 
increase of Y3MSH was observed 15 minutes post-oCRF infusion, which paralleled 
a similar increase in plasma cortisol. Gel filtration chromatography revealed 
that the observed increase was attributable to elevations of 9K and 4K forms 
of Y MSH 
3 
immunoreactivity. Affinity chromatography demonstrated that the 
majority of Y3MSH immunoreactivity in human plasma is glycosylated. As the 
smaller forms of Y3MSH are felt to have endocrine activity at the adrenal 
cortex, these changes may be physiologically relevant. 
INTRODUCIION 
Y-melanotropin (Y3MSH) is a 27-residue peptide found within the 
N-terminal domain of proopiomelanocortin (POMC) containing the sequence 
His-Phe-Arg-Trp in common with c1- and a-MSH (21). There are two major dibasic 
cleavage sites in the 16K N-terminal region of POMC, potentially generating 
the extreme N-terminal peptide, Y3MSH, and joining peptide, that segment 
between YMSH and adrenocorticotropiz5(t$$H). 
associate a with joining peptide (POMC - 
In theory, Y3MSH could thus be 
depending on the extent of glycosylation),' 
estimated molecular weight 8-lOK, 
POMC (POMC1-77, 
the extreme N-terminal fragment of 
estimated molecular weight 9-llK), or alone (POMC51-77, 
molecular weight 3-4K). In humans, an additional cleavage site is located 
within Y3MSH, 
11-residue, 
potentially yielding a 12-residue peptide (Y2MSH), or an 
C-amidated peptide, YIMSH (18). These theoretical products, 
however, have not been demonstrated in human anterior pituitary (33,35), and a 
larger peptide is assumed to be the circulating form in plasma (32,33). 
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The extent of processing of Y-melanotropin in the plasma of 
physiologically normal humans has.not been elucidated. Metapyrone has been 
shown to facilitate an elevation of Y-melanotropin in normal humans (15) which 
is attributable to an elevation of 16K-sized material (33), presumably the 
intact N-terminal domain of POMC. The existence of more processed, smaller 
forms of circulating Y-melanotropin, however, may be physiologically relevant. 
Y3MSH, for example, is able to bind to the adrenal cortex (25), and can 
potentiate ACTH-induced adrenal steroidogenesis (1,2,13,24). Additionally, 
Y2MSH has been demonstrated to have potent cardiovascular (8,9,17) and renal 
(19) effects, as well as the ability to induce behavioral changes in rats 
(23). No potential physiological effects, however, have been demonstrated of 
any of the possible larger forms of Y-melanotropin. 
The release of Y-MSH from the anterior pituitary into plasma is probably 
mediated by corticotropin releasing factor 
b 
CRF). 
for the N-terminal domain of POMC (POMCls7 ), 
Using an antibody specific 
Chan et al. (10) demonstrated 
that this larger form of Y-melanotropin, ACTH, and B-endorphin were released 
in equimolar amounts following ovine CRF (oCRF) stimulation of cultured human 
anterior pituitary cells. Several reports (14,20) have since indicated that 
total plasma Y3MSH immunoreactivity (IR) increases in normal humans following 
oCRF infusion, but the specific forms released (i.e., Y3MSH, the entire 16K 
N-terminal domain of POMC, or intermediate-sized products) were not 
determined. As CRF is likely a physiological mediator of Y3MSH release, and 
the extent of processing of circulating Y3MSH-IR may reflect relevant 
endocrine activity, we undertook the present investigation to explore the 
effect of oCRF infusion on the pituitary release into plasma of the various 
possible forms of Y3MSH-IR in normal human males. 
METHODS 
Subjects. Seven male volunteers (age 20-30) were studied. Each subject had 
an unremarkable medical history as well as normal physical and psychiatric 
examinations. Each had normal laboratory tests including an 
electrocardiogram, serum electrolytes and glucose, liver, renal, and thyroid 
function tests, complete blood count and a urine drug screen. Written 
informed consent was obtained from each subject for participation in this 
study. 
Preparation of CRF. Synthetic ovine CRF (synthesized and characterized by 
J.R. and W.V.) was prepared for injection by the University of Michigan 
Medical Center Pharmacy. Ten to 12 mg of material was dissolved in 10 ml of a 
vehicle solution of 5% human albumin, 0.9% benzyl alcohol, 0.001 N HCl, 0.1% 
lactose and 0.01% ascorbic acid, and was sterilized by filtration. This 
material was then diluted ten-fold in 0.9% NaCl containing 0.001 N HCl. This 
stock material was diluted another ten-fold with the original vehicle above, 
yielding a theoretical concentration of 10 ug/ml. This solution was stored in 
1 ml aliquots in sterile amber glass bottles at -2O'C until use. Random vials 
were assayed for both oCRF immunoreactivity and biological activity in rat 
anterior pituitary cell cultures (36). For injection, vials were thawed 10 
minutes prior to infusion; all transfer syringes and needles were coated with 
vehicle solution, and the oCRF was diluted in this vehicle to a final 
concentration equivalent to 0.1 ug/kg body weight for each subject (total 
volume injected 0.2-0.5 ml). 
270 
Infusion paradigm. Subjects presented to the Clinical Research Center of the 
University of Michigan at 12:30 p.m., after having their usual lunch. 
Intravenous catheters were inserted in the median antecubital veins of both 
arms. One catheter was fitted with a heparin lock for withdrawal of blood 
samples; the other catheter was maintained open with a slow drip of isotonic 
intravenous fluid for injection purposes. At 1:30 p.m., a control injection 
of 0.9% saline was given; at 2:00 p.m., a vehicle-control injection was given. 
At 2:20 p.m., 175-200 ml of blood was withdrawn for plasma Y MSH 
determination. At 2:30 p.m., 0.1 ug/kg oCRF was injected (over 1 -15 a 
seconds), followed by a 1 ml flush with vehicle. We have previously found 
that the maximum response to oCRF of plasma B-endorphin and Y3MSH levels 
occurs between 10 and 15 minutes post-oCRF infusion (unpublished observation). 
Accordingly, at 2:45 p.m. a second 175-200 ml blood sample was obtained for 
Y3MSH quantitation. In addition, plasma was obtained for cortisol 
determination 5 minutes before and 15 minutes after the saline and vehicle 
injections as well as 5 minutes before and at 5, 10, 15, 30, 60 and 120 
minutes following the oCRF infusion. Subjects were kept supine throughout the 
procedure, and had blood pressure and pulse monitored every 15 minutes. No 
subject reported any subjective experience from the infusion of oCRF; the 
experiment was terminated at 4~30 p.m. This paradigm is summarized in the 
lower portion of Figure 1. 
Sample Preparation. Blood samples were obtained via the previously described 
intravenous cannulae. Samples for Y3MSH determination were collected into 
chilled EDTA-containing vacutainers and were immediately centrifuged at 4'C; 
the resulting plasma was acidified to pH 2 with 1N HCl, and immediately stored 
at -7oOc. For extraction, the plasma samples were pooled as either pre- or 
post-oCRF infusion for each subject. The pooled plasma samples were then 
extracted with Sep-Pak Cl8 cartridges as has been previously described for 
extracting B-endorphin from human plasma (7). We consistently achieve 85-90% 
recovery of Y3MSH using this procedure. The extracts were then lyophilized 
and the dried material stored at -7O'C until further processing. 
Blood samples for corticosteroid determination were collected into 
chilled heparin-containing vacutainers. These samples were immediately 
centrifuged at 4'C, the plasma removed and stored at -7O'C until assayed. 
Gel chromatrography. Extracted plasma samples prepared for Y MSH 
determination (equivalent to 80-100 ml of plasma) were resuspended in 40 8 ul 
0.1% formic acid and applied to a Sephadex G-50 column (0.9 X 90 cm). The 
column was developed in 0.1% formic acid, and 2 ml fractions collected. Each 
fraction was dried by lyophilization, and resuspended in methanol/O.1 N HCl 
(50/50) for Y3MSH quantitation by radioimmunoassay. Recovery of Y3~s~-1~ from 
this column was 90%. 
Assays. Y3MSH concentrations were determined by a specific radioimmunoassay 
that we have develo ed. 
of Y3MSH (His5-Arg lp4 
The antibody is directed against a midportion region 
), and was raised in rabbits against synthetic bovine 
Y MSH 
8 
conjugated to bovine serum albumin (34). The assay was performed in a 
5 mM phosphate buffer, pH 7.6, containing 0.12M NaCl, 0.004M EDTA, 0.016% 
NaN3, 1.6% rabbit serum, and 0.1% polylysine. The standards (synthetic human 
Lys-Y3MSH) and samples were added in 50 ul methanol/O.1 N HCl (50/50). The 
antiserum was added in 100 ul of buffer, at a final dilution.of 1:25,000. The 
radioligand was human [1251]-Ly~-Y3MSH, which was iodinated by the 
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chloramine-T method [16]; 20,000 counts in 100 ul of buffer were added per 
tube. The assay was run in a final volume of 250 ul under disequilibrium 
conditions for 48-72 hrs at 4'C. Separation was by immunoprecipitation by 
addition of 15 ul of sheep-anti-rabbit IgG per tube. This assay has a 
sensitivity of < 1 fmoles/tube, an IC20 of 2 fmoles/tube, and an IC50 of 32 
fmoles/tube under disequilibrium conditions. Samples containing Y3MSH-IR in 
this study typically were read in the portion of the standard curve resulting 
in 20-30% inhibition. The antiserum has less than 1% cross-reactivity with 
1(1=H, Lys-ylMSH, y2MSH, B-endorphin, ACTH, a-MSH, B-MSH, B-endorphin, and 
met-enkephalin. The intrassay coefficient of variation is 4.9%, and the 
interassay coefficient of variation is 10.8%. 
Total plasma corticosteroids were quantitated by the competitive protein 
binding technique of Pegg and Keane (26) as modified by de la Pena and 
Goldzieher (11). The sensitivity of this assay is 0.3 ug/dl. The intra- and 
inter-assay coefficients of variation are 2.0% and 7.1X, respectively. 
Concanavalin A Affinity Chromatography. The pre- and post-oCRF infusion 
plasma samples from subjects 6 and 7 were subjected to gel filtration 
chromatography as described above, and those fractions corresponding to 4 + 1K 
and 9 + lK, as well as the fractions constituting the void volume of-the 
column T> 13K) for each subject and for each condition (pre- and post-oCRF) 
were pooled. These samples were dried by lyophilization. To determine if the 
Y3MSH IR in these peaks existed in a glycosylated form, each peak was 
subjected to Concanavalin A (Con A) - Sepharose 4B chromatography, as 
described by Shibasaki et al. (30). Briefly, samples were resuspended in 500 
ul of buffer and applied to a 500 ul Con A column that had been equilibrated 
with buffer. Glycosylated peptides were eluted by increasing concentrations 
of o-methyl-D-mannopyranoside and finally O.lM acetic acid. 1 ml fractions 
from these columns were collected, dried, and assayed for Y3MSH by the 
previously described RIA. 
Statistics. Comparisons between pre- and post-OCRP infusion levels of 
IR-y3MSH and cortisol were by paired t-tests. Results are means + S.E.M. 
unless stated otherwise. 
RESULTS 
We desired to demonstrate that any effect we might find on plasma Y3MSH 
levels in this study was specific to the oCRF infusion, as opposed to any 
non-specific stress effects. The average response of plasma cortisol to oCRF 
is shown in Figure 1. The mean baseline cortisol level remained unperturbed 
by the control injections, but showed a rapid increase within 10 minutes of 
the oCRF injection, returning to baseline levels after several hours. These 
data suggest that the oCRF is pI$siologically active and able to reach the 
pituitary and facilitate the release of POMC-derived peptides (i.e., ACTH, as 
indirectly observed by the increase in plasma cortisol), and that the 
endocrine effect seen is specific to the oCRF injection, and not a stress 
response to injections per se (as indicated by unchanging baseline cortisol 
levels pre- and post-control injections). 
The y3MSH-IR from a typical subject is shown in Figure 2. 
Immunoreactivity both pre- and post-oCRF infusion was found in fractions of 
the void volume of the Sephadex G-50 column (molecular weight > 13K), in 
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fractions of 8-10K (fractions #31-35), and in a collection of smaller peaks of 
3.1-5.OK (fractions 841-55). In several subjects (including the one shown in 
Figure 2), several fractions with molecular weights less than 3.1K contained 
y3MSH-IR. The immunoreactivity in these fractions presumably is due to 
smaller forms of y3MSH, although not to the predicted cleavage products Y2MSH 
or YlMSH, as the antiserum does not recognize these specific peptides. The 
total plasma y3MSH-IR before and after oCRF infusion for each subject is 
summarized in Figure 3. Each subject manifested an increased plasma level of 
total Y3MSH-IR after injection of oCRF, ranging from a 1.3 to 16.5 fold 
elevation. The mean group change from pre- to post- infusion was from 0.26 + 
0.09 fmoles/ml to 0.53 + 0.11 fmoles/ml, a 2.0 fold increase (t = -3.146, p < 
0.01). Similarly, the mean group plasma cortisol levels measured at the same 
two time points increased 2.4 fold, from 6.14 + 1.21 ug/dl to 14.98 + 1.83 - 
ug/dl (t = -8.393, p < 0.0005). 
To determine which forms of Y3MSH-IR contributed to the observed 2-fold 
increase of total YMSH-IR, 
("4K"), 8-IOK ("9K"?, 
the amount of immunoreactivity found in the 3-5K 








Catheter Saline 1 OCRF 
Inserted Vehicle Injections 
13:@3hrs 14:oo 
9 
15:oo 16:OO 17:oo 
Time 
Figure 1. Plasma cortisol levels in seven subjects at various times before 
and after control and oCRF injections. Data are means + S.E.M. The lower 
half of the figure summarizes the times of the injections and sample 
collections. 
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9 A Pre-CRF 
Vo 12.4K 4.5K 3.lK Vt 
B Post-CRF 
30 40 50 
Fraction Number 
Figure 2. Representative Sephadex G-50 gel filtration profiles of ‘f MSH-IR in 
extracted plasma samples both pre- and post-oCRF infusion (Su&ect 3). 
Molecular weights of peptide standards are 
4.5K, [I~~~]-ACTH; 3.1K, [I~~~]-Y~MSH). 
indicated (12.4K, cytochrome C; 
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oCRF infusion was determined from the gel filtration elution profiles (Figure 
2) for each subject. These data are shown in Figure 4. The total increase of 
Y3MSH-IR was attributable to elevations of both the 9K fractions, which rose 
from a mean level of 0.79 fmoles/ml to 2.08 fmoles/ml (t = -1.609, p < O.l), 
and the 4K fractions, which increased from 0.10 to 0.19 fmoles/ml (t = -2.515, 
p < 0.025). There was no increase observed for the immunoreactivity found in 
the void fractions. 
Because Y3MSH has been reported to exist in a glycosylated form in bovine 
anterior pituitary as determined by Con A affinity chromatography [30], we 
attempted to determine if human plasma Y3MSH-IR was glycosylated in two of 
these subjects. The 4K, 9K and void fractions, both pre- and post-oCRF 
infusion were found to be glycosylated. Between 80 and 100% of the ~~~~~~~~ 
in the 4K fractions was retained by Con A columns; 89-100% of the 9K fractions 
and 69-100% of the void volume fractions were similarly retained. A 
representative experiment is summarized in Figure 5. 
less than 
In a control experiment, 
10% of synthetic human Y3MSH was retained by a Con A column. 
2( 
Pre-CRF Post-CRF PrekRF PO&CRF 
Figure 3. Plasma concentrations 
subjects both pre- 
of total Y3MSH-IR and cortisol in seven 
and 15 minutes post-oCRF infusion. The increase of mean 
plasma level (dotted lines) from pre- to post-oCRF infusion is significant for 
























































































































































































































































































































































































































































































































































































































































































































































Ovine CRF infusion in the present study resulted in a doubling of total 
YSMSH-IR in normal men, in reasonable agreement with several previous studies. 
Motomatsu and co-workers (20) found up to a two-fold increase in circulating 
levels of immunoreactive N-terminal peptide (POMC1-76) after injection of 100 
ug of oCRF in 4 subjects. Hale and co-workers (14), using a radioimmunoassay 
specific for Y3MSH demonstrated about a 1.5-fold increase in YSMSH-IR 
following injection of 100 ug of oCRF in 6 subjects. Using a much smaller 
dose of oCRF (5-7 ug), we were able to observe increases of the same order as 
previous investigators employing much higher oCRF doses. We selected the 0.1 
ug/kg dose of oCRF as we found in an earlier study (Watson, S.J., Lopez, J., 
Young, E.A., Vale, W., Rivier, J., Akil, H., submitted) that this results in 
plasma levels of oCRF in the normal physiological range. It may be that the 
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Fraction Number 
Figure 5. Representative elution profile of Y MSH-IR in plasma from a 
Concanavalin A (Con A)-Sepharose 4B affinity 4 co umn. Plasma samples were 
chromatographed on a Sephadex G-50 column as described in the text, and the 
4K, 9K, and void volume peaks pooled. Each peak was then chromatographed on a 
Con A-Sepharose 4B affinity column. Glycosylated material was eluted with 
increasing concentratons of o-methyl-D-mannopyranoside @MM) and O.lM acetic 
acid (AcoH). This profile is for the 4K fractions of subject 6 following oCRF 
infusion. 
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after being exposed to this low-dose infusion of oCRF, so that the infusion of 
more oCRF, at least in the short run, is incapable of facilitating the release 
of more Y3MSH. 
The forms of Y3MSH-IR released following oCRF stimulation in normal 
humans have not been elucidated (14,20 
2* 
Using an antibody directed against 
the N-terminal peptide of POMC (PoMCl- 6), Chan et al, (10) demonstrated the 
release of two forms of Y-MSH-IR, a B-lipotropin-sized (lo-1lK) and a larger 
form, from cultured human anterior pituitary cells following oCRF stimulation. 
The major forms of Y3MSH-IR detected in the present investigation were 4K and 
9K forms, presumably representing native, glycosylated Y3MSH, and Y MSH 
extended with the extreme N-terminal fragment of POMC (4,10,14,19, 8), 3 
although extension of Y3MSH with joining peptide has been reported in porcine 
pituitary (6). One might argue that larger forms were present, but due to 
sample collection or processing methods, breakdown was allowed to occur and we 
measured these breakdown products instead of the native circulating forms. 
While this is a possibility it seems unlikely, as this same procedure 
preserves intact the multiple molecular species of ACTH and B-endorphin. 
Inspection of Figure 1 indicates several peaks in the 3-5K range. The column 
system utilized for separation in this study is one we have previously 
developed for resolving different forms of R-endorphin; the observed peaks 
actually differ from each other only by a few hundred daltons. The reason for 
this heterogeneity is not apparent, but probably reflects variable degrees of 
glycosylation of intact Y3MSH, or some other form of post-translational 
modification. 
While smaller forms of Y3MSH-IR exist in human plasma under normal 
physiological conditions, it may be that the processing of the N-terminal 
domain of POMC is altered in various pathological states. A number of 
investigators have determined the sizes of Y MSH-IR under other conditions. 
Nakao et al. (22) demonstrated a large form IB-lipotropin-sized, lo-1lK) in 
plasma from patients with Addison's and Nelson's syndromes. Another report 
(5) showed a 16K form in Nelson's syndrome patients' plasma, and both a 16K 
and a smaller form in tumor extract and plasma of a patient with ectopic ACTH 
syndrome, Tanaka et al. (33) showed an increase in 16K-sized Y3MSH-IR 
following metyrapone in normal males. In general, the observed forms of 
Y3MSH-IR in these non-physiological states tends to be large. Of interest, 
however, is the report of Watsman et al. (35),,which demonstrated elevations 
of 4K, 
arrest). 
6K and 11K forms of Y3MSH-IR following "maximal stress" (cardiac 
While cardiac arrest cannot be considered a "normal" stressor, it 
would cause maximal driving of physiological regulatory mechanisms; it is of 
note that these authors found smaller forms of Y3MSH-IR under these 
circumstances. The release of smaller forms of Y3MSH-IR following oCRF 
stimulation has not been previously reported; the results of the present study 
suggest that this physiological perturbation results in the release of 
processed forms of Y3MSH. 
The release of smaller, processed forms of Y 3MSH-IR under physiological 
conditions may be endocrinologically relevant. The smallest form of Y3MSH-IR 
(y MSH, 3-4K) has been shown to have the ability to bind to the adrenal cortex 
(2% and enhance ACTH-induced steroidogenesis (1,2,13,24). No physiological 
action has been demonstrated for the larger forms of Y3MSH-IR. It is 
interesting to note that the vast majority of circulating Y MSH-IR at both 
rest and post-CRF stimulation is of 4K and 9K sizes. On the ot er hand, there b 
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have been several communications (12,27,29,31) indicating that human pituitary 
contains predominately a larger form (i.e., B-lipotropin-sized) of Y3MSH-IR, 
similar to reports of bovine pituitary (3,32). Young et al. (37), however, 
have recently demonstrated in the rat that although B-lipotropin is the 
primary product stored in the anterior lobe, CRF promotes the preferential 
release of B-endorphin into plasma. Thus, the findings of the current study 
are not altogether surprising; it may be that in the human, the POMC products 
B-endorphin and Y3MSH are stored in the pituitary as larger peptides, but the 
smaller, possibly more biologically active forms may be preferentially 
released. 
We also determined that the circulating forms of Y3MSH-IR in human plasma 
are to a large extent glycosylated. The determination of glycosylation of 
Y3MSH has not been previously reported in human plasma, but is in agreement 
with the finding of glycosylated forms of Y3MSH-IR in bovine anterior and 
intermediate pituitary (30) and in human pituitary (4). The significance of 
this post-translational modification is not known, but may facilitate the 
biochemical activity of this peptide, or may protect it from intracellular 
degradation (30). 
The function of Y3MSH is not known, That circulating levels of 
processed, possibly physiologically active forms of this peptide are 
significantly elevated following oCRF infusion suggests that Y3MSH serves a 
role in modulating the neuroendocrine responses of the 
hypothalamic-pituitary-adrenal axis. 
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